Board summary
Key figures
67,559
Registered population
52.9% aged 18–64
30.9%
Aged 65+
ICB 19.0% · England 17.9%
4.3%
Ethnic minority (non-White)
2.0% Asian · England 9.6%
4.8%
In IMD quintile 1
ICB 31.9% · England 21.0%
~3,449
Core20 residents (est.)
Resident basis; registered basis ~2,865 · see page 3
13,992
Hypertension register
+8.12% in 3 yrs · England +5.60%
598
SMI register
15% of Wirral (LAD)'s
1,286
COPD register
Reviews -2.20% in 3 yrs
Forecast to 2030
16,412
Hypertension patients, 2030
+2,420 on today
78.5%
QRISK ≥20% on statins, 2030
+5.95pp over 3 yrs
7.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage fell behind national growth.
Asthma reviews reached 63.3% (England 65.7%) after falling 1.7% over 2023 to 2025 (England +4.4%), which may reflect recall strain.
Hypertension treatment to target trails comparators.
Blood pressure control is 65.8% against 67.9% in Wirral (LAD), 69.1% in the ICB and 70.3% in England, which may reflect review delays.
Breast and cervical screening exceed national rates.
Breast screening reaches 77.0% (England 69.9%) and cervical screening reaches 73.3% (England 66.8%), showing strong preventive uptake across the PCN.
Population, age and ethnicity
Patients aged 65 and over represent 30.9% of the PCN registered population
Healthier West Wirral PCN serves 67,559 registered patients across five practices. Patients aged 65 and over make up 30.9% of the list (20,911 patients), notably above Wirral (20.7%), NHS Cheshire and Merseyside ICB (19.0%) and England (17.9%). Working-age adults (18–64) comprise 52.9% and children aged 0–17 represent 16.2%. Projected list growth to 2030 is 0.8% under unverified modelling (Wirral 1.2%, ICB 2.3%, England 2.3%). By Census residential estimates, White ethnic groups represent 95.7% (Wirral 95.2%, ICB 93.0%, England 81.1%), leaving an ethnic minority share of 4.3%. High older-age concentration may intensify local frailty and multimorbidity workload.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Wirral (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wirral LA) | 1,517 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 76.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.2% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wirral LA) | 753 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wirral LA) | 25.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is low overall but Core20 patients concentrate entirely in two practices
The PCN Core20 share is 4.8%, well below Wirral (LAD) at 34.8%, the ICB at 31.9% and England at 21.0% (average IMD decile 7.8 vs England 5.5). A 0.51 percentage point reconciliation difference exists between PCN (4.8%) and weighted practice share (4.2%). By concentration and volume, registered Core20 patients sit in Myrtle Group Practice (11.4%, estimated 2,361 patients) and Upton Group Practice (6.6%, estimated 504 patients), while three practices record 0.0%. Core20PLUS5 resources must target these two practices rather than spreading PCN funding evenly.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
598
SMI register
0.87% recorded prevalence
318
Learning disability register
0.46% recorded prevalence
32
Care homes, 1,223 beds
In the PCN catchment
10.9%
Provide unpaid care
Wirral (LAD), Census 2021
The PCN records 318 learning disability patients (0.5% prevalence) and 598 severe mental illness patients (0.9%), alongside 32 catchment care homes with 1,223 beds. Both prevalence rates trail Wirral (0.8% and 1.2%), NHS Cheshire and Merseyside ICB (0.6% and 1.1%) and England (0.6% and 1.0%). Lower recorded prevalence does not establish under-detection or unmet need, though proactive annual health checks remain essential.
Severe mental illness: physical health checks
PCN SMI blood pressure checks reached 81.7% (England 83.4%), BMI recording 74.4% (England 82.1%), and psychosis alcohol recording 68.3% (England 81.8%). Checks trail at Myrtle Group Practice (75.5%) and Greasby Group Practice (76.0%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
13,992
Hypertension register
+8.12%
Register growth, 3 yrs
Wirral (LAD) +6.35% · England +5.60%
+1.67pp
BP control, under 80
≤140/90 · +1.09pp aged 80+
+2,420
More patients by 2030
Forecast 16,412 (23.90%)
Hypertension case-finding and control
Recorded hypertension prevalence is 20.4% (13,992 patients), exceeding Wirral (18.0%), the ICB (16.8%), and England (15.2%), alongside 3-year growth of +8.1% (England +5.6%). However, blood pressure control trails comparators: 86.6% had a recent reading (England 90.0%) and 65.8% reached target (England 70.3%). By age, control is 62.6% for under-80s (Wirral 66.5%, ICB 66.4%, England 67.8%) and 77.0% for those aged 80+ (Wirral 80.1%, ICB 80.0%, England 81.2%). Crude prevalence is not age-adjusted. Trailing blood pressure control across age cohorts may reflect recall or treatment titration gaps, which clinical audit could test.
Lipids and statins
QRISK ≥ 20% lipid therapy reached 64.7% (Wirral 65.8%, ICB 63.2%, England 63.6%), following +10.1% 3-year growth (England +6.2%). Diabetic secondary prevention statin coverage is 81.6%, trailing Wirral (85.1%), the ICB (83.8%), and England (84.4%). Trailing statin coverage in diabetes may reflect review gaps that targeted practice audits could test.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 156,192 | £1.90 | £1.71 | £1.86 | £296,765 |
| Cardiovascular (all), 2025 | 209,862 | £6.33 | £4.37 | £3.33 | £1,328,426 |
Across 156,192 prescribed items for lipid-regulating drugs (2026), cost per item was £1.90 (Wirral £2.00, ICB £1.71, England £1.86). The PCN spends £29,676 more than at NHS Cheshire and Merseyside Integrated Care Board's unit cost. Higher unit cost than the ICB may reflect formulary choices rather than prescribing inefficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−1.67%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.77%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.5% across 4,933 patients, but annual reviews fell 1.7% over 2023 to 2025 (England +4.4%) to 63.3% (England 65.7%), leaving an estimated 1,810 unreviewed patients. The COPD register expanded +12.1% over 2023 to 2025 to 1,286 patients (prevalence 1.9%, England 1.9%), yet annual reviews fell 2.2% (England +2.8%) to 71.9% (England 76.4%, Wirral 73.2%). Declining reviews alongside register growth may reflect capacity pressure rather than clinical exception.
Cancer register and children's immunisation
Cancer QOF prevalence (all ages) is 6.2% at PCN level, exceeding Wirral (4.8%), NHS Cheshire and Merseyside Integrated Care Board (4.3%), and England (3.8%). This difference does not establish under-detection or coding quality; higher recorded prevalence may reflect an older population demographic.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Healthier West Wirral PCN records a 6.2% cancer prevalence (4,219 patients), exceeding England's 3.8% and Wirral's 4.8%. PCN breast screening reaches 77.0% (England 69.9%) and cervical screening reaches 73.3% (England 66.8%). For wider system context, NHS Cheshire and Merseyside ICB diagnosed 55.5% of cancers at stage 1 or 2 in 2022 (7,482 of 13,490 with a known stage), compared to England's 55.3% and the 75.0% national ambition by 2028. Known stage was recorded for 72.8% of ICB cancers (13,490 of 18,522; England 67.0%). Strong PCN screening operates within wider ICB early-stage diagnosis constraints, indicating that primary care detection must connect closely with secondary pathways.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Wirral University Teaching Hospital NHS Foundation Trust achieved 77.6% on the 62-day cancer referral to treatment standard against the 85.0% target, above England (71.2%) and below Countess of Chester Hospital NHS Foundation Trust (83.3%). On the 28-day faster diagnosis standard, the trust reached 74.7% against the 75.0% standard (England 79.3%). Trust 6+ week diagnostic waits were 1.5% for MRI and 1.5% for CT (England 21.4% and 9.9%). These provider metrics describe acute system performance rather than PCN delivery; trailing treatment standards alongside low diagnostic waits may reflect downstream secondary care constraints.
| Pathways within standard (%) | Wirral | Liverpool | Countess of Chester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.71 | 75.47 | 87.37 | 77.25 | 79.32 |
| 31-day treatment (96%) | 92.53 | 90.51 | 93.48 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.65 | 73.26 | 83.28 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wirral | Liverpool | Countess of Chester | England |
|---|---|---|---|---|
| MRI | 1.54 | 6.42 | 11.26 | 21.40 |
| CT | 1.55 | 0.71 | 4.18 | 9.92 |
| Echocardiography | 5.07 | 12.55 | 31.44 | 28.48 |
| Colonoscopy | 32.81 | 33.14 | 26.44 | 30.83 |
| Gastroscopy | 17.73 | 44.99 | 27.52 | 29.02 |
| All 15 DM01 tests | 5.02 | 11.50 | 20.16 | 23.14 |
| Community services activity | Wirral residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 58,870 | 541,280 |
| Referrals | 13,315 | 97,150 |
| Patients with a contact | 17,205 | 146,240 |
Community services (residents of Wirral), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 66.1% of community service contacts among Wirral local authority residents (38,930 of 58,870 contacts). These borough-level resident contacts reflect wider community services activity rather than PCN performance.
Practice variation and patient experience
Practice variation appears across clinical domain points and childhood MMR dose completion
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Upton | 119 | 6.6 | 69.5% | 75.8% | 81.2% |
| West Wirral | 124 | 0.0 | 49.1% | 60.1% | 77.8% |
| Marine Lake | 110 | 0.0 | 50.3% | 59.4% | 76.2% |
| Greasby | 101 | 0.0 | 48.7% | 73.6% | 74.8% |
| Myrtle | 117 | 11.4 | 51.6% | 74.4% | 66.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve of 25 compared measures trail England, led by falling chronic disease reviews
Twelve of 25 compared measures trail England over three years. Over 2023 to 2025, annual reviews fell 3.1% for heart failure (England +8.7%), 2.2% for COPD (England +2.8%), and 1.7% for asthma (England +4.4%), while mental health BMI recording rose +1.1 pp (England +5.1 pp). Conversely, breast screening rose +11.8% (England +8.4%) to 77.0% (England 69.9%), and QRISK ≥ 20% lipid therapy grew +10.1% (England +6.2%). Falling reviews alongside screening gains may reflect differing recall capacity, which local workload audits could test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
Dementia register
COPD reviews
BMI record (SMI)
Diabetes statin (no CVD)
QRISK statin treatment
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wirral (LAD) | Asset | PCN | Wirral (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 32 (1,223 beds) | n/a | Schools (catchment) | 71 | n/a |
| Children's centres | 4 | 16 | Places of worship | 53 | 171 |
| Libraries | 7 | 18 | Primary schools (LA maintained) | 12 | 52 |
| Primary academies | 14 | 36 | Special schools | 3 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma review coverage is 63.3% (England 65.7%) and fell 1.7% over 2023 to 2025 (England +4.4%), leaving an estimated 1,810 of 4,933 patients unreviewed. For discussion: the PCN could run structured asthma recall with after-school and flexible slots, starting at the two practices holding all Core20 patients. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension recall and titration clinics
Across 13,992 hypertension patients (20.4% prevalence), blood pressure control is 65.8% (England 70.3%; Wirral 67.9%) and 62.6% in under-80s (England 67.8%). For discussion: practices could deploy clinical pharmacist-led recall and medicines titration for patients above target, prioritising under-80s in Core20 practices. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Combined chronic disease and SMI recall
Reviews trail England for heart failure at 67.4% (England 78.5%; 3-year change -3.1% vs +8.7%), COPD at 71.9% (England 76.4%), and SMI BMI at 74.4% (England 82.1%). For discussion: the PCN could combine multimorbidity and SMI reviews, starting at Myrtle Group Practice (75.5%) and Greasby Group Practice (76.0%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Proactive care home multidisciplinary reviews (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Sustain cervical screening coverage (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension recall and titration clinics (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Combined chronic disease and SMI recall (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
